Immunogenicity and protective efficacy of sars-cov-2 mrna vaccine encoding secreted non-stabilized spike in female mice

HIGHLIGHTS

• who: Eakachai Prompetchara from the able to elicit robust, specific antibody and, cell responsesChulaCov, vaccination could provide, % protection from severe clinical signs and mortality in mice. It also markedly reduced viral RNA burden in serum and tissues. With such promising results from animal studies, the same formulation of ChulaCov, vaccine that had been tested in animals is currently in phase, of clinical trials and can be manufactured locally for later clinical development. This program is a strong foundation for the fight against the next pandemic by increasing preparedness to make mRNA vaccine widely and timely accessible for . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.